A new oral isocitrate dehydrogenase 1 inhibitor:olutasidenib
Olutasidenib is a potent,selective,oral small molecule inhibitor targeting mutant isocitrate dehydrogenase-1(IDH1),which was developed by Forma Therapeutics.It is approve by the FDA on December 1,2022,for the treatment of adult patients with relapsed or refractory acute myeloid leukemia with a susceptible IDH1 mutation.Clinical studies have shown that olutasidenib has a good efficacy and safety profile.Common adverse effects include nausea,fatigue discomfort,ar-thralgia,constipation,leukocytosis,dyspnea,fever,rash,mucositis,diarrhea,and elevated transaminase.In this paper,the mechanism of action,pharmacokinetics,clinical efficacy evaluation,and adverse reactions of olutinib were reviewed in order to provide reference for clinical rational drug use.
NETL
NSTL
万方数据
